Subretinal fluid in macular edema secondary to branch retinal vein occlusion

• Published in: Scientific reports 2024-06, Vol.14 (1), p.13623-6
• Main Authors: Jee, Donghyun, Park, Soyoung, Kwon, Jin-woo
• Format: Article
• Language: English
• Subjects: 692/53/2422; 692/53/2423; 692/699/3161/3175; Acuity; Aged; Aged, 80 and over; Angiogenesis Inhibitors - therapeutic use; Atrophy; Clinical outcomes; Edema; Female; Humanities and Social Sciences; Humans; Interleukin 8; Macular Edema - drug therapy; Macular Edema - etiology; Macular Edema - metabolism; Macular Edema - pathology; Male; Middle Aged; multidisciplinary; Occlusion; Patients; Placenta growth factor; Retina; Retinal Vein Occlusion - complications; Retinal Vein Occlusion - drug therapy; Retinal Vein Occlusion - metabolism; Retinal Vein Occlusion - pathology; Science; Science (multidisciplinary); Subretinal Fluid - metabolism; Tomography, Optical Coherence; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - metabolism; Visual Acuity
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-64047-y

We identified characteristics of patients with subretinal fluid (SRF) in macular edema (ME) secondary to branch retinal vein occlusion (BRVO) and determined their clinical outcomes after anti-vascular endothelial growth factor (VEGF) treatment. Fifty-seven eyes of BRVO patients with ME were divided into two groups according to the presence or absence of SRF at diagnosis. We compared the aqueous profiles, ocular and systemic characteristics at baseline, and the clinical outcomes. The SRF group had significantly greater central subfield thickness (CST) values and poorer best-corrected visual acuity (BCVA) at baseline compared to the non-SRF group. The former group had significantly higher aqueous levels of interleukin-8, VEGF, and placental growth factor. CST reduction and BCVA improvement during treatment were significantly greater in the SRF group than in the non-SRF group. Consequently, CST values were significantly lower in the SRF group than in the non-SRF group at 12 months, when BCVA did not differ significantly between the two groups. The SRF group required more frequent anti-VEGF treatment over 12 months and exhibited a higher rate of macular atrophy. Based on the aqueous profiles and the number of treatments required, the presence of SRF in BRVO patients appears to be associated with higher disease activity.